despit
new
agent
develop
shortterm
benefit
patient
colorect
cancer
crc
metastat
crc
cure
rate
improv
due
high
rate
leucovorin
oxaliplatin
folfox
resist
clinic
therapeut
plateau
time
treatment
regim
lead
signific
toxic
cost
patient
inconveni
drugresist
link
crc
stem
cell
associ
epidermaltomesenchym
transit
emt
pathway
thu
optim
treat
crc
therapi
target
cell
surviv
emt
pathway
crc
bulk
stem
cell
popul
critic
recent
identifi
novel
small
molecul
effect
alon
combin
potenti
growth
inhibit
crc
bulk
folfoxresist
crc
stem
cell
vitro
vivo
model
present
studi
report
synthesi
anticrc
evalu
sever
stabl
effect
analog
identifi
one
equipot
analog
inhibit
growth
crc
bulk
cell
sensit
folfoxresist
cell
reduc
sphere
format
capac
crc
stem
cell
appear
complex
mechan
cytotox
includ
abrog
phase
reduct
phosphoryl
increas
stain
activ
caspas
cleavag
enhanc
ratio
reduc
phosphoryl
indirect
effect
sinc
inhibit
activ
vitro
kinas
assay
find
suggest
singl
agent
combin
develop
therapeut
agent
crc
bulk
folfoxresist
crc
stem
cell
popul
unmanag
metastat
crc
condit
despit
attempt
improv
patient
outcom
incorpor
new
activ
system
agent
clinic
practic
littl
improv
metastat
crc
patient
cure
rate
spite
use
without
addit
therapi
erad
metastat
diseas
cur
surgeri
crc
cancer
relaps
within
first
year
follow
treatment
complet
suggest
rel
rapid
repopul
neoplast
progeni
ie
crc
stem
cell
aggress
treatment
higher
prolong
dose
multipl
drug
combin
oxaliplatin
lead
seriou
sideeffect
despit
frequent
use
cancer
thorough
understand
mechan
action
intervent
overcom
resist
still
rel
limit
one
mechan
resist
occur
induct
emt
pathway
downregul
epitheli
marker
apc
bcatenin
ecadherin
characterist
emt
pathway
emt
involv
crc
stem
cell
invas
metastasi
drugresist
effort
develop
effect
drug
minim
side
effect
profil
normal
epitheli
cell
crc
treatment
recent
identifi
novel
tetraazaadamantan
contain
small
molecul
decan
either
alon
combin
potenti
growth
inhibit
crc
heterogen
bulk
folfoxresist
crc
stem
cell
maintain
integr
normal
colon
epitheli
cell
nitrogen
contain
adamantan
analog
eg
great
interest
conform
constrain
motif
design
variou
pharmacolog
tool
structur
uniqu
azaadamantan
relat
physic
chemic
properti
notabl
reduct
lipophil
thu
induc
higher
aqueou
solubl
compound
compar
adamantan
consist
sole
carbon
hydrogen
atom
howev
studi
biolog
activ
azaadamantan
deriv
still
rel
less
explor
despit
good
pharmacolog
properti
repres
exampl
motif
fig
includ
receptor
agonist
modul
neuron
nicotin
acetylcholin
receptor
nachr
inhibitor
cn
relat
diseas
cancer
inhibitor
human
tcell
leukemia
antivir
analges
agent
furthermor
natur
product
ansabananin
abn
inhibit
sar
coronaviru
scv
natur
alkaloid
dapholdamin
b
daphnezomin
possess
moieti
fig
recent
diazaadamantan
deriv
report
inhibitor
rimantadineresist
strain
influenza
apuerto
viru
noteworthi
although
methenamin
clinic
use
prevent
urinari
tract
infect
tetrazaadementan
skeleton
bare
util
design
small
druglik
molecul
except
synthes
crucial
reaction
intermedi
phenacyl
amin
uniqu
tetraazaadamentan
methenamin
analog
identifi
recent
group
show
activ
resist
stem
cell
expect
mechan
action
crc
inhibit
checkpoint
kinas
pathway
indirect
mechan
sinc
play
critic
role
cell
cycl
regul
respons
dna
damag
sever
inhibitor
develop
test
chemosensit
agent
compound
shown
inhibit
phosphoryl
vitro
vivo
crc
model
howev
pharmacokinet
analysi
show
short
plasma
halflif
similar
short
plasma
halflif
like
due
presenc
reactiv
alkyl
chlorid
group
overcom
problem
design
synthes
sever
novel
tetraazaadamantan
analog
test
cytotox
efficaci
crc
bulk
folfoxresist
well
crc
stem
cell
structur
optim
focus
mainli
replac
reactiv
alkyl
chlorid
group
stabl
alkyl
alkenylaryl
moieti
rational
reactiv
alkyl
chlorid
potenti
react
protein
thiol
amin
compromis
plasma
halflif
thu
biolog
activ
function
replac
cholo
cl
group
chosen
enhanc
overal
stabil
molecul
retain
possibl
enhanc
potenc
fig
addit
approach
modif
also
includ
satur
olefin
group
shorten
alkyl
chain
length
replac
nitrogen
tetraazaadmantan
ring
phosphoru
labil
valenc
shell
electron
fig
novel
g
f
analog
prepar
depict
scheme
compound
synthes
reaction
readili
avail
tetraazaadamantan
variou
alkenyl
halid
ch
cl
reflux
condit
quantit
yield
scheme
evalu
differ
activ
nitrogen
correspond
phosphoru
analog
also
synthes
isoster
analog
lead
compound
react
reflux
condit
ch
cl
differ
alkenyl
halid
furnish
correspond
phosphoru
analog
excel
yield
scheme
butyl
chlorid
analog
boron
acid
analog
also
synthes
use
similar
reaction
condit
reflux
h
h
respect
diversifi
structur
activ
relationship
studi
azaadamantan
deriv
synthes
azaadamantan
analog
depict
scheme
compound
synthes
react
readili
avail
phenacyl
chlorid
ch
cl
reflux
condit
good
yield
scheme
structur
novel
deriv
confirm
h
nmr
c
nmr
hrm
analysi
compound
puriti
analyz
analyt
highperform
liquid
chromatographi
hplc
proceed
vitro
biolog
assay
determin
ic
novel
azaadamantan
g
h
azaphosphaadamantan
analog
cell
mttcell
surviv
assay
result
show
variabl
rang
ic
analog
base
result
cell
viabil
assay
structureact
relationship
sar
infer
first
reduc
olefin
doubl
bond
retain
chlorin
atom
reduc
potenc
compound
cancer
cell
viabil
second
replac
chlorin
atom
phenyl
retain
activ
molecul
remov
chlorin
atom
led
reduc
potenc
tabl
third
isoster
phosphor
analog
ie
ie
display
moder
cell
viabil
compar
parent
nitrogen
analog
isoster
phosphoru
analog
exhibit
poor
activ
tabl
compound
boron
acid
function
also
led
reduc
potenc
fourth
among
analog
design
replac
chlorin
atom
phenacyl
group
differ
alkyl
chain
length
analog
phenyl
ic
mm
phenyl
ic
mm
display
moder
inhibit
cell
viabil
design
extend
alkyl
chain
length
lost
activ
tabl
overal
except
replac
cl
group
phenyl
group
modif
structur
includ
chain
length
function
group
variat
isoster
replac
nitrogen
phosphor
caus
dramat
reduct
total
loss
cytotox
cell
tabl
compound
show
ic
rang
mm
analog
show
poor
inhibitori
activ
cell
tabl
among
analog
exhibit
low
micromol
rang
ic
mm
close
ic
mm
tabl
thu
identifi
lead
novel
compound
potenc
compar
result
suggest
cl
activ
group
respons
cytotox
activ
compound
appear
pharmacolog
stabl
favor
develop
next
determin
whether
enhanc
potenc
crc
cell
result
show
treatment
reduc
ic
cell
line
dosedepend
manner
similar
tabl
result
indic
analog
reduc
effect
dose
inhibit
growth
crc
cell
thu
potenti
effect
current
therapi
determin
whether
inhibit
surviv
folfoxresist
cell
line
perform
mttcell
surviv
assay
compar
result
inde
treatment
effect
sensit
cell
line
ic
mm
mm
respect
similar
slightli
better
ic
ic
mm
mm
respect
cell
line
tabl
sinc
growth
folfoxresist
cell
line
maintain
continu
presenc
mm
mm
oxaliplatin
effect
reduc
ic
cell
line
independ
oxaliplatin
treatment
recent
studi
shown
inhibit
spheroid
format
activ
crc
stem
cell
determin
whether
similar
activ
crc
stem
cell
experi
use
wellcharacter
crc
stem
cell
line
perform
sphere
format
assay
involv
threedimension
cultur
system
serumfre
condit
result
show
inhibit
growth
sphere
similar
tabl
ic
cell
greater
ic
heterogen
popul
crc
bulk
cell
line
suggest
cell
resist
drug
crc
bulk
cell
recent
year
mani
anticanc
drug
discov
target
cell
cycl
checkpoint
arrest
cell
prolifer
time
provid
opportun
repair
damag
dna
consequ
lead
drug
resist
cell
surviv
therefor
current
effort
induc
death
arrest
cell
use
inhibitor
checkpoint
kinas
known
therapeut
activ
link
replic
stress
one
mechan
sever
induc
replic
stress
pathway
implic
therapeut
agent
enhanc
replic
stress
perturb
sg
checkpoint
cancer
cell
mitot
catastroph
induc
accumul
singlestrand
dna
ssdna
doublestrand
dna
dsdna
break
exce
repair
capac
cell
lead
cell
death
recent
studi
shown
treatment
increas
phase
arrest
cell
cycl
hydroxyurea
hu
treatment
pure
induc
replic
stressdepend
phase
arrest
present
studi
cell
treat
mm
h
mm
addit
h
fig
cell
cycl
analysi
result
show
phase
arrest
cell
fig
howev
combin
treatment
phase
arrest
continu
g
phase
arrest
abrog
interestingli
combin
abrog
phase
increas
g
phase
arrest
fig
structur
differ
seem
import
differenti
activ
two
compound
cell
cycl
profil
phosphoryl
subsequ
phosphoryl
effici
progress
dna
replic
fork
prevent
fork
stall
therefor
impair
dna
repair
cellular
divis
inhibitor
singl
agent
combin
chemotherapeut
agent
may
import
research
wellestablish
atrmedi
phosphoryl
play
critic
role
dna
replic
dna
repair
sg
phase
checkpoint
control
target
cancer
therapi
also
shown
inhibit
abrog
sphase
progress
sinc
abrog
phase
arrest
determin
phosphoryl
level
treatment
either
alon
combin
hu
pure
induc
phase
arrest
experiment
protocol
describ
combin
treatment
fig
compar
lane
howev
treatment
alon
affect
phosphoryl
fig
compar
lane
result
suggest
block
huinduc
phosphoryl
thu
involv
abrog
phase
seen
fig
determin
whether
also
block
phosphoryl
observ
bulk
cell
cell
line
treat
differ
concentr
h
result
show
inhibit
dosedepend
manner
fig
seen
bulk
cell
fig
increas
phosphoryl
cell
howev
cell
reduc
dosedepend
manner
fig
differenti
effect
two
cell
line
may
due
statu
cell
express
mutant
cell
express
wildtyp
howev
mechan
might
regul
phosphoryl
two
cell
line
current
unknown
blockag
replic
uv
hydroxyurea
treatment
activ
pathway
stall
replic
fork
lead
doublestrand
dna
break
dsb
cell
cycl
arrest
apoptosi
atr
phosphoryl
histon
variant
form
consid
marker
dsb
previous
shown
inhibit
gemcitabin
treatment
increas
level
atrmedi
replic
stress
present
studi
examin
whether
toxic
either
alon
combin
relat
dsb
phosphoryl
examin
level
ihc
stain
cell
treatment
protocol
given
fig
observ
increas
treatment
alon
cell
increas
combin
fig
thu
result
show
either
alon
combin
induc
replic
stressmedi
dna
damag
cell
compound
inhibit
activ
reconstitut
purifi
system
cellbas
studi
clear
inhibit
phosphoryl
cell
know
whether
inhibit
phosphoryl
direct
indirect
mechan
direct
mechan
perform
vitro
kinas
assay
use
purifi
protein
result
show
inhibit
activ
compound
tabl
next
test
whether
kinas
may
target
compound
profil
activ
kinas
vitro
assay
system
find
signific
inhibit
see
tabl
supplementari
materi
result
becam
clear
inhibit
phosphoryl
directli
caus
possibl
due
unknown
mechan
remain
elucid
atr
one
key
activ
phosphoryl
promot
autophosphoryl
kinas
play
import
role
cell
cycl
control
dna
replic
studi
inhibit
phosphoryl
caus
indic
atr
may
target
howev
possibl
complet
rule
atr
includ
kinas
profil
assay
also
possibl
indirectli
inhibit
protein
claspin
serv
scaffold
protein
atrmedi
phosphoryl
downregul
claspin
express
shown
inhibit
activ
respons
replic
stress
studi
await
examin
whether
inhibit
phosphoryl
due
downregul
claspin
furthermor
might
downregul
mammalian
tor
complex
activ
turn
may
downregul
phosphoryl
induc
phosphoryl
howev
yet
experiment
verifi
role
inhibit
phosphoryl
previou
studi
increas
express
bax
import
member
famili
proapoptot
effect
implic
better
surviv
colorect
cancer
patient
hand
increas
express
prevent
apoptosi
inhibit
activ
bax
thu
increas
ratio
play
critic
role
determin
suscept
apoptosi
cancer
cell
determin
effect
treatment
express
apoptot
marker
protein
eg
cleav
caspas
parap
determin
correl
ratio
cell
result
show
increas
level
cleav
caspas
cell
treatment
suggest
increas
level
apoptosi
cell
line
fig
apoptot
effect
support
increas
ratio
fig
b
aim
check
druglik
compound
explor
lipinski
paramet
two
potent
compound
use
filter
lipinski
veber
rule
embed
discoveri
studio
ds
client
accelri
san
diego
ca
usa
summar
tabl
accord
lipinski
rule
compound
molecular
weight
mw
greater
da
hydrogen
bond
acceptor
hba
hydrogen
bond
donor
hbd
five
octanolwat
partit
coeffici
logp
valu
like
poor
absorpt
membran
permeat
physiolog
condit
similarli
veber
et
al
base
studi
rat
suggest
compound
rotat
bond
would
good
oral
avail
closer
inspect
tabl
show
show
complianc
lipinski
well
veber
indic
topolog
polar
surfac
area
tpsa
indic
hydrogen
bond
form
capabl
molecul
also
comput
predict
use
tool
ds
drug
target
human
protein
report
psa
henc
consid
import
indic
predict
bioavail
drug
candid
oral
absorpt
tpsa
around
exhibit
complianc
tpsa
indic
tabl
suggest
potenti
develop
drug
molecul
conclus
sar
base
novel
analog
led
identif
show
compar
potenc
inhibit
growth
crc
bulk
sensit
folfoxresist
reduc
sphere
format
capac
crc
stem
cell
experi
evalu
underli
mechan
action
reveal
abrog
phase
reduc
phosphoryl
increas
stain
increas
express
apoptot
marker
protein
thu
compound
potenti
develop
therapeut
agent
effect
singl
agent
combin
solid
mechanist
basi
target
pathway
crc
heterogen
bulk
crc
stem
cell
popul
melt
point
record
fischerjohn
melt
point
apparatu
uncorrect
h
nmr
spectra
record
bruker
advanc
instrument
cdcl
oper
mhz
chemic
shift
report
valu
ppm
j
valu
report
hertz
hz
signal
quot
singlet
doublet
triplet
multiplet
dd
doublet
doublet
highresolut
ms
record
ab
sciex
tripletof
instrument
pennsylvania
state
univers
univers
park
experi
perform
nitrogen
atmospher
ovendri
glasswar
reagent
start
materi
anhydr
solvent
purchas
commerci
supplier
use
receiv
reaction
cours
monitor
thinlay
chromatographi
tlc
precoat
silica
gel
f
aluminum
sheet
merck
darmstadt
germani
spot
visual
uv
light
crude
reaction
product
purifi
recrystal
ethanolmethylen
chlorid
mixtur
tetraazaadamantan
triazaphophaadamanatn
variou
alkyl
alkenylaryl
halid
phenacyl
deriv
purchas
commerci
sourc
puriti
final
compound
quantifi
analyt
high
perform
liquid
chromatographi
analysi
compar
peak
area
product
rel
impur
synthesi
accomplish
laboratori
follow
procedur
warmu
et
al
describ
recent
studi
mixtur
mmol
alkenyl
halid
mmol
ch
cl
ml
reflux
h
reaction
h
reaction
complet
reaction
indic
tlc
reaction
mass
cool
room
temperatur
filter
residu
wash
excess
methylen
dichlorid
crude
solid
thu
obtain
recrystal
etohch
cl
mixtur
dri
vacuum
mm
afford
correspond
pure
analog
mixtur
g
mmol
g
mmol
aceton
ml
reflux
h
complet
reaction
indic
tlc
reaction
mixtur
cool
room
temperatur
filter
residu
wash
excess
aceton
crude
solid
thu
obtain
recrystal
etohch
cl
mixtur
dri
vacuum
mm
afford
correspond
pure
analog
yield
g
white
solid
mp
c
mixtur
g
mmol
phenyl
boron
acid
g
mmol
ch
cl
ml
reflux
h
complet
reaction
indic
tlc
reaction
mass
cool
room
temperatur
filter
residu
wash
excess
ch
cl
crude
solid
thu
obtain
recrystal
etohch
cl
mixtur
dri
vacuum
mm
afford
correspond
pure
analog
yield
g
white
solid
mp
c
gener
procedur
synthesi
novel
azaadamantan
analog
mixtur
azaadamantan
mmol
phenacyl
chlorid
mmol
ch
cl
ml
reflux
h
complet
reaction
indic
tlc
reaction
mass
cool
c
residu
filter
wash
excess
methylen
dichlorid
crude
solid
thu
obtain
recrystal
mixtur
etoh
ch
cl
dri
vacuum
mm
c
afford
correspond
pure
human
colon
cancer
cell
line
obtain
american
type
cultur
collect
atcc
rockvil
md
cell
maintain
recommend
atcc
either
mccoy
dulbecco
modifi
eagl
medium
dmem
gl
dglucos
supplement
fb
antibioticantimycot
tissu
cultur
flask
humidifi
incub
c
atmospher
air
carbon
dioxid
medium
chang
two
time
week
cell
passag
use
trypsinedta
folfoxresist
cell
line
obtain
dr
adhip
p
majumdar
john
dingel
va
medic
centr
detroit
mi
cell
gener
exposur
clinic
relev
dose
schedul
expos
schedul
cycl
cycl
last
one
week
briefli
cell
first
expos
folfox
mm
mm
oxaliplatin
h
surviv
cell
cultur
normal
medium
without
drug
day
cycl
repeat
time
surviv
cell
split
expos
higher
dose
folfox
mm
mm
oxaliplatin
mm
mm
oxaliplatin
day
per
week
approxim
week
final
resist
cell
maintain
normal
cultur
medium
contain
low
dose
folfox
mm
mm
oxaliplatin
crc
stem
cell
line
obtain
dr
emina
huang
lerner
research
institut
cleveland
oh
describ
recent
public
cell
character
express
esa
high
stem
cell
marker
cell
maintain
medium
contain
gml
dglucos
mgml
nahco
mg
ml
bovin
serum
albumin
mm
glutam
mgml
insulin
transferrin
selenium
nm
progesteron
mgml
putrescin
antibioticantimycot
solut
ultralow
attach
plate
cultur
maintain
humidifi
incub
c
atmospher
air
carbon
dioxid
surviv
cell
determin
mtt
bromid
assay
atcc
manassa
va
principl
viabl
cell
number
directli
proport
purpl
formazan
color
reduc
mtt
dye
quantit
measur
spectrophotometri
briefli
cell
plate
quadruplet
flatbottom
tissu
cultur
plate
treatment
compound
certain
period
describ
respect
figur
legend
ml
mtt
reagent
ad
well
incub
c
h
allow
format
purpl
color
crystal
formazan
total
ml
deterg
solut
ad
well
reaction
mixtur
incub
dark
h
room
temperatur
develop
color
densiti
measur
spectrophotometr
nm
use
polarstar
omega
micropl
reader
bmg
labtech
inc
cari
nc
live
cell
seed
ultralow
attach
plate
next
day
cell
treat
differ
concentr
either
alon
combin
cell
incub
day
number
spheroid
count
control
treat
group
olympu
invert
microscop
magnif
determin
cell
cycl
profil
cell
plate
mm
tissu
cultur
dish
grown
confluenc
cell
treat
mm
h
follow
treatment
mm
addit
h
describ
previous
treatment
cell
harvest
differ
time
interv
wash
icecold
pb
process
fac
analysi
rang
g
g
g
phase
arrest
subg
apoptot
cell
establish
basi
correspond
dna
content
histogram
minimum
cell
count
sampl
level
variou
protein
determin
western
blot
analysi
previous
describ
procedur
antibodi
gapdh
purchas
cell
signal
technolog
danver
determin
whether
kinas
inhibitor
vitro
kinas
activ
determin
eurofin
pharma
discoveri
servic
wolverhampton
uk
determin
whether
inhibit
kinas
profil
kinas
test
reaction
biolog
corp
malvern
pa
experi
repeat
least
three
time
result
express
mean
se
oneway
analysi
varianc
anova
calcul
sigmaplot
onetail
ttest
use
compar
signific
differ
control
treat
group
criterion
statist
signific
p
western
blot
data
band
intens
measur
use
imagej
normal
gapdh
